{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4","value":"-3"},{"groupId":"OG001","spread":"58","value":"-25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Naive CD4 T cells will be defined according to co-expression of CD3, CD4, CD45RA, and CCR7. Positive results indicate an increase in the number of cells between baseline and 4 weeks. Negative results indicate a decrease in the number of cells between baseline and 4 weeks.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.","id":"OG000","title":"Arm I (Palifermin)"},{"description":"Patients do not receive palifermin.","id":"OG001","title":"Arm II (no Palifermin)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline and 4 weeks after administration of palifermin","title":"Changes in the Number of Naive CD4 T Cells in the Blood","type":"SECONDARY","unitOfMeasure":"cells per microliter of blood"}